Browsing "Patent Infringement Drugs"
Adderal XR Claims Construction: Shire, Impax & Barr
Introduction Barr and Impax seek to launch generic versions of Shire Lab’s ADHD drug Adderal XR®. Shire sued Barr in [...]
Adderall XR: Shire Shares Rise on Settlement With Barr
Bloomberg By Etain Lavelle – Aug 15, 2006 Shire Plc shares rose after the company settled a patent lawsuit with [...]
Augmentin 1: Early Ruling Favors Generics
February 21, 2002 Introduction. Augmentin (an oral, anti-bacterial drug) is a combination of amoxicillin and potassium clavulnate (a beta-lactamase inhibitor). [...]
Augmentin 2: Federal Trial Judge splits decision
March 1, 2002 GlaxoSmithKline announced that a federal judge in the United States District Court for the Eastern District of [...]
Claritin 1: Judge likely to deny Summary Judgment
June 26, 2002 Introduction. On June 25, 2002, a federal judge in Newark[1] heard oral arguments on the validity of [...]
Claritin 2: Schering Plough loses Claritin Patent Protection
August 9, 2002 By GARDINER HARRIS Staff Reporter of THE WALL STREET JOURNAL A federal judge threw out Schering-Plough Corp.’s [...]
Levaquin®: JNJ likely to prevail against Mylan
October 18, 2002 A. Introduction and Summary The patent infringement case brought by Johnson & Johnson and Daiichi against Mylan [...]
Levaquin®: as predicted, the Court Bars Mylan’s launch
January 6, 2005 Introduction On December 23, 2004, Federal Judge Irene Keeley in Morgantown, West Virginia decided in favor of [...]
Neurontin 1: Interim Status Report
Introduction. Neurontin, is Pfizer’s (formerly Warner-Lambert’s) $ 2 billion a year FDA-approved epilepsy medication. Warner Lambert’s first generation patents have [...]
Neurontin 2: Generic Competition likely in September ‘02
The battle over Neurontin (whose active ingredient is gabapentin) is heating up: A hearing is scheduled for Monday, September 9, [...]
Related Case Type
